Overview

* Cipher Q2 2025 revenue rises 152% yr/yr to quarterly record of $13.4 mln, beats estimates

* Adjusted EBITDA for Q2 2025 grows 148% and beats analyst expectations

* Company repaid $15 mln debt and repurchased $2.1 mln shares in Q2 2025

Outlook

* Cipher aims to grow Natroba market share in U.S. anti-parasitic market

* Company intends to acquire complementary dermatology products

Result Drivers

* NATROBA SALES - Natroba sales in the U.S. contributed $7.8 mln, a sequential increase of 16% over Q1 2025

* EPURIS GROWTH - Epuris sales volumes grew 14% in Q2 2025 compared to Q2 2024

* LICENSING REVENUE DECLINE - Licensing revenue decreased due to competitive pressures and contractual royalty rate reductions

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $13.4 $12.90

Revenue mln mln (4

Analysts

)

Q2 Net $5.89

Income mln

Q2 Beat $7.59 $6.41

Adjusted mln mln (4

EBITDA Analysts

)

Q2 $8.56

EBITDA mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Cipher Pharmaceuticals Inc ( CPHRF ) is C$16.00, about 15.4% above its August 7 closing price of C$13.54

* The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)